IDH2 and neoplasm: Moreover, in preclinical models of JAK2/IDH-mutant MPNs, the combination of JAK2 and IDH inhibitors showed a strong inhibition of tumor growth and suppression of abnormal 2-hydroxyglutarate production [193].